AbbVie, Coherus BioSciences autoimmune news
The U.S. Patent Trial and Appeal Board instituted an inter partes review petition from Coherus challenging a patent covering AbbVie’s autoimmune drug Humira adalimumab. Coherus’ CHS-1420, a biosimilar of Humira, is in Phase III testing for psoriasis and rheumatoid arthritis. Coherus is challenging U.S. Patent No. 8,889,135, which covers methods of treating RA with a 40 mg subcutaneous dose of an anti- tumor necrosis factor (TNF) alpha antibody administered every other week. PTAB determined that Coherus has a reasonable likelihood of demonstrating the patent’s claims are unpatentable on the grounds of obviousness. The ‘135 patent expires on Jan. 4, 2025. AbbVie’s U.S. composition of matter patent covering Humira is set to expire in December. The company’s U.S. method patents covering the mAb against TNF alpha will begin expiring in 2022. A final decision from PTAB is due within a year. ...